🚀 VC round data is live in beta, check it out!
Absci Valuation Multiples
Discover revenue and EBITDA valuation multiples for Absci and similar public comparables like Nextbiomedical Co, PureTech Health, Benitec Biopharma, Bicycle Therapeutics and more.
Absci Overview
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Founded
2011
HQ
Employees
157
Website
Financials (LTM)
EV
$253M
Absci Financials
Absci reported last 12-month revenue of $7M and negative EBITDA of ($104M).
In the same LTM period, Absci generated $7M in gross profit, ($104M) in EBITDA losses, and had net loss of ($109M).
Revenue (LTM)
Absci P&L
In the most recent fiscal year, Absci reported revenue of $5M and EBITDA of ($86M).
Absci expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | $7M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($104M) | XXX | ($86M) | XXX | XXX | XXX |
| EBITDA Margin | (1511%) | XXX | (1892%) | XXX | XXX | XXX |
| EBIT Margin | (1663%) | XXX | (2341%) | XXX | XXX | XXX |
| Net Profit | ($109M) | XXX | ($103M) | XXX | XXX | XXX |
| Net Margin | (1578%) | XXX | (2274%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Absci Stock Performance
Absci has current market cap of $399M, and enterprise value of $253M.
Market Cap Evolution
Absci's stock price is $2.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $253M | $399M | 0.0% | XXX | XXX | XXX | $-0.69 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbsci Valuation Multiples
Absci trades at 36.7x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
Absci Financial Valuation Multiples
As of March 21, 2026, Absci has market cap of $399M and EV of $253M.
Equity research analysts estimate Absci's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Absci has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $399M | XXX | $399M | XXX | XXX | XXX |
| EV (current) | $253M | XXX | $253M | XXX | XXX | XXX |
| EV/Revenue | 36.7x | XXX | 55.8x | XXX | XXX | XXX |
| EV/EBITDA | (2.4x) | XXX | (2.9x) | XXX | XXX | XXX |
| EV/EBIT | (2.2x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 36.7x | XXX | — | XXX | XXX | XXX |
| P/E | (3.7x) | XXX | (3.9x) | XXX | XXX | XXX |
| EV/FCF | (1.1x) | XXX | (3.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Absci Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Absci Margins & Growth Rates
Absci's revenue in the last 12 month grew by 224%.
Absci's revenue per employee in the last FY averaged $0.0M.
Absci's rule of 40 is (1287%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Absci's rule of X is (951%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Absci Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 224% | XXX | (18%) | XXX | XXX | XXX |
| EBITDA Margin | (1511%) | XXX | (1892%) | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (1287%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (951%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 497% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1089% | XXX | 1408% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2502% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Absci Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nextbiomedical Co | XXX | XXX | XXX | XXX | XXX | XXX |
| PureTech Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Benitec Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicycle Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Autolus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Absci M&A Activity
Absci acquired XXX companies to date.
Last acquisition by Absci was on XXXXXXXX, XXXXX. Absci acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Absci
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAbsci Investment Activity
Absci invested in XXX companies to date.
Absci made its latest investment on XXXXXXXX, XXXXX. Absci invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Absci
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Absci
| When was Absci founded? | Absci was founded in 2011. |
| Where is Absci headquartered? | Absci is headquartered in United States. |
| How many employees does Absci have? | As of today, Absci has over 157 employees. |
| Who is the CEO of Absci? | Absci's CEO is Sean McClain. |
| Is Absci publicly listed? | Yes, Absci is a public company listed on Nasdaq. |
| What is the stock symbol of Absci? | Absci trades under ABSI ticker. |
| When did Absci go public? | Absci went public in 2021. |
| Who are competitors of Absci? | Absci main competitors are Nextbiomedical Co, PureTech Health, Benitec Biopharma, Bicycle Therapeutics. |
| What is the current market cap of Absci? | Absci's current market cap is $399M. |
| What is the current revenue of Absci? | Absci's last 12 months revenue is $7M. |
| What is the current revenue growth of Absci? | Absci revenue growth (NTM/LTM) is 224%. |
| What is the current EV/Revenue multiple of Absci? | Current revenue multiple of Absci is 36.7x. |
| Is Absci profitable? | No, Absci is not profitable. |
| What is the current EBITDA of Absci? | Absci has negative EBITDA and is not profitable. |
| What is Absci's EBITDA margin? | Absci's last 12 months EBITDA margin is (1511%). |
| What is the current EV/EBITDA multiple of Absci? | Current EBITDA multiple of Absci is (2.4x). |
| What is the current FCF of Absci? | Absci's last 12 months FCF is ($239M). |
| What is Absci's FCF margin? | Absci's last 12 months FCF margin is (3468%). |
| What is the current EV/FCF multiple of Absci? | Current FCF multiple of Absci is (1.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.